Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity HCT for Resistant LCH
NCT00618540Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2007
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in Langerhans cell histiocytosis (LCH), sponsored by Masonic Cancer Center. Started Jan 2007; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT00618540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00618540.